Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetics of Response to GLP1R Agonists
NCT05071898Phase 1Recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Apr 2022
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of semaglutide in obesity, sponsored by University of Maryland, Baltimore. Primary endpoints: First phase insulin secretion at 6 weeks, Second phase insulin secretion at 6 weeks and 1 more. Started Apr 2022; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05071898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05071898.